Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Deferred Revenue (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Current Deferred Revenue for 8 consecutive years, with $8.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 57.74% year-over-year to $8.2 million, compared with a TTM value of $8.2 million through Dec 2025, down 57.74%, and an annual FY2025 reading of $8.2 million, down 57.74% over the prior year.
  • Current Deferred Revenue was $8.2 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $12.7 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $71.5 million in Q1 2024 and bottomed at $8.2 million in Q4 2025.
  • Average Current Deferred Revenue over 5 years is $34.6 million, with a median of $38.5 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue skyrocketed 140.13% in 2021, then tumbled 82.28% in 2025.
  • Year by year, Current Deferred Revenue stood at $43.5 million in 2021, then tumbled by 34.12% to $28.6 million in 2022, then surged by 56.48% to $44.8 million in 2023, then tumbled by 56.47% to $19.5 million in 2024, then plummeted by 57.74% to $8.2 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ARCT at $8.2 million in Q4 2025, $12.7 million in Q1 2025, and $19.5 million in Q4 2024.